HRS-6257

HRS-6257 is an investigational small molecule analgesic developed by Shanghai Hengrui Pharmaceutical, a subsidiary of Jiangsu Hengrui Pharmaceuticals. It functions as a highly selective inhibitor of the voltage-gated sodium channel Nav1.8 (Sodium channel protein type 10 subunit alpha). Nav1.8 is predominantly expressed in peripheral sensory neurons and is a key mediator in the generation and conduction of action potentials in nociceptors. By targeting this specific channel, HRS-6257 is designed to provide effective pain management for acute and chronic conditions while minimizing the side effects typically associated with non-selective sodium channel blockers or opioid analgesics. The drug is currently undergoing Phase 1 clinical trials to assess its safety, pharmacokinetics, and the impact of food on its bioavailability in healthy volunteers.